Breaking News

Galapagos Earns Janssen Milestone

January 16, 2013

Delivers second preclinical drug candidate

Galapagos NV has identified a second preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering a $5.3 million milestone payment to Galapagos.
 
The two companies entered the alliance in 2007, under which Janssen has option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs.  
 
"We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers